跳转至内容
Merck
  • Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations.

Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations.

Medical mycology (2013-09-06)
Ildikó Nyilasi, Sándor Kocsubé, Krisztina Krizsán, László Galgóczy, Tamás Papp, Miklós Pesti, Katalin Nagy, Csaba Vágvölgyi
摘要

The investigation of the antifungal activities of drugs whose primary activities are not related to their antimicrobial potential is in the current forefront of research. Statin compounds, which are routinely used as cholesterol-lowering drugs, may also exert direct antimicrobial effects. In this study, the in vitro antifungal activities of various statins (lovastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin and pravastatin) were examined against one isolate each of four dermatophyte species (Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum canis and Microsporum gypseum). Basically, statins were effective in inhibiting all dermatophyte studied, but were particularly active against M. canis and T. mentagrophytes. Fluvastatin and simvastatin were active against all of the tested fungi causing a complete inhibition of their growth at very low concentrations (6.25-12.5 μg/ml). Lovastatin and rosuvastatin had inhibitory effects at higher concentrations (25-128 μg/ml), while atorvastatin and pravastatin proved the less effective. The in vitro interactions between statins and different antifungals (ketoconazole, itraconazole, fluconazole, amphotericin B, nystatin, griseofulvin, terbinafine and primycin) were also investigated using a standard chequerboard broth microdilution method. Synergetic interactions were observed in several cases, most of them were noticed when statins were combined with terbinafine and the different azoles. Some combinations were particularly active (ketoconazole-simvastatin or terbinafine-simvastatin), as they were found to exert synergistic effect against all of the investigated isolates. The other antifungals showed synergistic interactions with statins in only certain cases. These results suggest that statins exert substantial antifungal effects against dermatophyte fungi and they should be promising components in a combination therapy as they can act synergistically with a number of clinically used antifungal agents.

材料
货号
品牌
产品描述

Sigma-Aldrich
二甲基亚砜, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
二甲基亚砜, ACS reagent, ≥99.9%
Sigma-Aldrich
二甲基亚砜, for molecular biology
Sigma-Aldrich
二甲基亚砜, suitable for HPLC, ≥99.7%
Sigma-Aldrich
二甲基亚砜, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
二甲基亚砜, ReagentPlus®, ≥99.5%
Sigma-Aldrich
二甲基亚砜, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
二甲基亚砜, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
二甲基亚砜, anhydrous, ≥99.9%
Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
L-谷氨酰胺
Sigma-Aldrich
二甲基亚砜, BioUltra, for molecular biology, ≥99.5% (GC)
SAFC
L-谷氨酰胺
Sigma-Aldrich
氟康唑, ≥98% (HPLC), powder
Sigma-Aldrich
二甲基亚砜, puriss. p.a., dried, ≤0.02% water
Sigma-Aldrich
二甲基亚砜, PCR Reagent
Sigma-Aldrich
二甲基亚砜, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
伊曲康唑, ≥98% (HPLC)
Sigma-Aldrich
L-谷氨酰胺, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
酮康唑, 99.0-101.0% (EP, titration)
Supelco
氟康唑, Pharmaceutical Secondary Standard; Certified Reference Material
USP
氟康唑, United States Pharmacopeia (USP) Reference Standard
USP
二甲基亚砜, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Mevinolin from Aspergillus sp., ≥98% (HPLC)
Sigma-Aldrich
L-谷氨酰胺, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-谷氨酰胺
Supelco
酮康唑, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
酮康唑
Sigma-Aldrich
灰黄霉素, from Penicillium griseofulvum, 97.0-102.0%
Sigma-Aldrich
二甲基亚砜 溶液, 50 wt. % in H2O